CSPC Wins U.S. FDA Clearance for Clinical Trials of Novel Mpox mRNA Vaccine SYS6037
核心洞察
CSPC Pharmaceutical Group (搜索) received FDA approval to begin U.S. clinical trials for SYS6037 (搜索), an mRNA-based mpox (搜索) vaccine co-developed with the Institute of Microbiology of the Chinese Academy of Sciences (搜索).
The vaccine uses a single mRNA strand encoding multiple antigens, a design that simplifies manufacturing, improves quality control, and reduces production costs.
Preclinical data showed SYS6037 (搜索) demonstrated stronger immunogenicity and protective efficacy than a live-attenuated Tiantan-strain vaccine, along with broad cross-reactivity against Orthopoxvirus antigens.
CSPC Pharmaceutical Group (搜索) has secured approval from the U.S. Food and Drug Administration to commence clinical trials of SYS6037 (搜索), an mRNA-based vaccine designed to prevent disease caused by the mpox (搜索) virus. The vaccine, co-developed with the Institute of Microbiology of the Chinese Academy of Sciences (搜索), represents a significant advancement in the race to address mpox, which has triggered sporadic and clustered infections across multiple regions globally in recent years.
The actual developer of the vaccine is Jushi Biotech (搜索), a controlled subsidiary of CSPC Pharmaceutical, underscoring the group's strategy to advance its next-generation vaccine portfolio through its innovation platform. The product, designated as a Category 1 prophylactic biologic, was announced by both CSPC Pharmaceutical and its subsidiary CSPC Innovation on August 10.
A Streamlined mRNA Approach
SYS6037 (搜索) injection is a multi-antigen mpox (搜索) vaccine encoded by a single mRNA strand. The mpox virus belongs to the Orthopoxvirus genus of the Poxviridae family. The vaccine's technical hallmark lies in its streamlined mRNA technology pathway, which, compared to traditional vaccine manufacturing processes, offers superior advantages in quality control during production and can significantly reduce manufacturing costs. This not only enhances the stability and controllability of vaccine production quality but also implies that, if successfully commercialized, the vaccine could be made available at a more economical price point, improving global accessibility.
Preclinical Promise
Preclinical study data indicate that SYS6037 (搜索) demonstrates excellent potential. In head-to-head comparisons with a traditional live-attenuated vaccine based on the Tiantan strain, the mRNA vaccine exhibited superior immunogenicity, capable of inducing a stronger immune response, and delivered more pronounced protective efficacy. Furthermore, the product has shown broad-spectrum cross-reactivity against multiple Orthopoxvirus antigens, suggesting its protective scope may extend beyond a single mpox (搜索) virus strain, broadening future application prospects.
Strategic Implications
CSPC Pharmaceutical stated that SYS6037 (搜索) injection is poised to become a highly competitive mpox (搜索) vaccine product in the market and will further enrich the group's innovative product pipeline in the mRNA vaccine field. Securing U.S. FDA clinical trial clearance represents a key milestone on the product's path toward the global market and reflects CSPC Pharmaceutical's established R&D and regulatory filing capabilities on its mRNA technology platform, now aligned with international standards.